Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | COMT | P21964 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8987735 | 0.86 | ESR1 (0.41) | ALDH1A1ESR1ESR2CYP3A4MAPK1 | |
| SCHEMBL9872415 | 0.81 | KCNN4 (0.35) | ALDH1A1MAPK1COMTTAAR1ALOX15 | |
| SCHEMBL9911072 | 0.81 | CNR1 (0.36) | ALDH1A1ESR1ESR2CYP3A4KMT2A | |
| SCHEMBL198144 | 0.80 | KCNN4 (0.32) | ALDH1A1KCNN4 | |
| SCHEMBL1820792 | 0.78 | KDM4E (0.30) | KDM4EMAPTKMT2A | |
| Benzene SCHEMBL4593432 | 0.77 | TSHR (0.38) | ALDH1A1MAPT | |
| SCHEMBL28872444 | 0.77 | KCNN4 (0.48) | KCNN4 | |
| Biphenyl SCHEMBL9539322 | 0.76 | ALDH1A1 (0.33) | ALDH1A1MAPK1KMT2AKCNN4 | |
| SCHEMBL7492959 | 0.73 | SLC6A2 (0.41) | ALDH1A1ESR1ESR2CYP3A4TAAR1 | |
| SCHEMBL8115695 | 0.72 | KDM4E (0.35) | ALDH1A1ALOX15KDM4EKMT2AKCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249429-A1 | PROCESS FOR THE MANUFACTURE OF VALSARTAN | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20090111995-A1 | Process for the manufacture valsartan | NOVARTIS AG (CH) | 2009-04-30 | — | — | US | disclosed |
| EP-1546122-B8 | PROCESS FOR THE MANUFACTURE OF VALSARTAN | NOVARTIS AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| EP-1878729-A1 | INTERMEDIATE FOR THE MANUFACTURE OF VALSARTAN | Novartis AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| US-20060069268-A1 | Process for the manufacture of valsartan | DENNI-DISCHERT DONATIENNE | 2006-03-30 | — | — | US | disclosed |
| EP-1546122-A1 | PROCESS FOR THE MANUFACTURE OF VALSARTAN | Novartis AG (CH) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004026847-A1 | PROCESS FOR THE MANUFACTURE OF VALSARTAN | NOVARTIS AG (CH) | 2004-04-01 | — | — | WO | disclosed |
| US-5502191-A | CYCLIZATION, INTERMEDIATES FOR ANGIOTENSIN II RECEPTOR ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069268-A1 | Process for the manufacture of valsartan | AGTR1, AGTR2, AGT | ALDH1A1 882/4885ESR1 3395/4885ESR2 2374/4885 |
| US-20100249429-A1 | PROCESS FOR THE MANUFACTURE OF VALSARTAN | AGTR1, AGTR2, AGT | ALDH1A1 882/4885ESR1 3395/4885ESR2 2374/4885 |
| US-20090111995-A1 | Process for the manufacture valsartan | AGTR1, AGTR2, AGT | ALDH1A1 882/4885ESR1 3409/4885ESR2 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.